A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

María E Oliva, Arcot Rekha, Albert Yellin, Jacyr Pasternak, Maria Campos, Gilbert M Rose, Timothy Babinchak, Evelyn J Ellis-Grosse, Evan Loh, 301 Study Group, María E Oliva, Arcot Rekha, Albert Yellin, Jacyr Pasternak, Maria Campos, Gilbert M Rose, Timothy Babinchak, Evelyn J Ellis-Grosse, Evan Loh, 301 Study Group

Abstract

Background: Complicated intra-abdominal infections (cIAI) remain challenging to treat because of their polymicrobial etiology including multi-drug resistant bacteria. The efficacy and safety of tigecycline, an expanded broad-spectrum glycylcycline antibiotic, was compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI.

Methods: A prospective, double-blind, multinational trial was conducted in which patients with cIAI randomly received intravenous (IV) tigecycline (100 mg initial dose, then 50 mg every 12 hours [q12h]) or IV IMI/CIS (500/500 mg q6h or adjusted for renal dysfunction) for 5 to14 days. Clinical response at the test-of-cure (TOC) visit (14-35 days after therapy) for microbiologically evaluable (ME) and microbiological modified intent-to-treat (m-mITT) populations were the co-primary efficacy endpoint populations.

Results: A total of 825 patients received >or= 1 dose of study drug. The primary diagnoses for the ME group were complicated appendicitis (59%), and intestinal (8.8%) and gastric/duodenal perforations (4.6%). For the ME group, clinical cure rates at TOC were 80.6% (199/247) for tigecycline versus 82.4% (210/255) for IMI/CIS (95% CI -8.4, 5.1 for non-inferiority tigecycline versus IMI/CIS). Corresponding clinical cure rates within the m-mITT population were 73.5% (227/309) for tigecycline versus 78.2% (244/312) for IMI/CIS (95% CI -11.0, 2.5). Nausea (31.0% tigecycline, 24.8% IMI/CIS [P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [P = 0.435]) were the most frequently reported adverse events.

Conclusion: This study demonstrates that tigecycline is as efficacious as imipenem/cilastatin in the treatment of patients with cIAI.

Trial registration: ClinicalTrials.gov NCT00081744.

Figures

Figure 1
Figure 1
Patient disposition and analysis population.

References

    1. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997–1005. doi: 10.1086/378702.
    1. Gorbach SL. Intraabdominal infections. Clin Infect Dis. 1993;17:961–5.
    1. Lorber B, Swenson RM. The bacteriology of intra-abdominal infections. Surg Clin North Am. 1975;55:1349–54.
    1. Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, Vogel SB, Solomkin JS. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery. 1995;118:716–21.
    1. de Vera ME, Simmons RL. Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg. 1996;131:338–42.
    1. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 2003;31:2228–37. doi: 10.1097/01.CCM.0000087326.59341.51.
    1. Krobot K, Yin D, Zhang Q, Sen S, Altendorf-Hofmann A, Scheele J, Sendt W. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23:682–7. doi: 10.1007/s10096-004-1199-0.
    1. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother. 1999;43:738–44.
    1. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis. 2000;36:19–36. doi: 10.1016/S0732-8893(99)00092-9.
    1. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother. 2002;46:2595–601. doi: 10.1128/AAC.46.8.2595-2601.2002.
    1. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother. 2003;47:400–4. doi: 10.1128/AAC.47.1.400-404.2003.
    1. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000;38:177–9. doi: 10.1016/S0732-8893(00)00193-0.
    1. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother. 2000;44:2225–9. doi: 10.1128/AAC.44.8.2225-2229.2000.
    1. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother. 2003;52:138–9. doi: 10.1093/jac/dkg289.
    1. Low DE, Kreiswirth BN, Weiss K, Willey BM. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents. 2002;20:220–2. doi: 10.1016/S0924-8579(02)00132-2.
    1. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 2001;40:173–7. doi: 10.1016/S0732-8893(01)00269-3.
    1. Murray JA, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2, clinical trial [abstract] Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003;43:416.
    1. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, Loh E. Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal infections [abstract] Presented at the 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2004. Session #97, Control #3841, Presentation #L-992c.
    1. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) J Antimicrob Chemother. 2002;49:479–87. doi: 10.1093/jac/49.3.479.
    1. Muralidharan G, Getsy J, Mayer P, Paty I, Micalizzi M, Speth J, Wester B, Mojaverian P. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract] Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999;39:303.
    1. Muralidharan G, Mojaverian P, Micalizzi M, Raible DG, Troy SM. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrobial Agents and Chemotherapy. 2005;49:1656. doi: 10.1128/AAC.49.4.1656-1659.2005.
    1. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety and tolerability of tigcycline (GAR-936) in healthy Japanese males [abstract] Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002;42:22.
    1. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, Tigecycline 200 Study Group Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther. 2004;26:704–14. doi: 10.1016/S0149-2918(04)90070-7.
    1. Troy SM, Mauralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract] Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003. Poster A-22.
    1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64:63–88.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅